#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuroblastoma recurrent Palmar-plantar erythrodysaesthesia syndrome Osteopetrosis Thromboangiitis obliterans Von Hippel-Lindau disease Primitive neuroectodermal tumour Glomerulonephritis membranous Soft tissue necrosis Partial lipodystrophy Plasma cell myeloma Small cell lung cancer extensive stage Small cell lung cancer limited stage Anal cancer recurrent Cold type haemolytic anaemia Biliary cancer metastatic More trials…

    Learn about Rare Diseases

    Hereditary optic atrophy – Treatment Fabry’s disease – Treatment Myxofibrosarcoma – Trials in Disease Methylmalonic acidaemia – Diagnostics Usher’s syndrome Burkitt’s lymphoma – Diagnostics Synovial sarcoma metastatic – Treatment Chondrosarcoma – Trials in Disease Leiomyosarcoma recurrent – Treatment Primary biliary cholangitis – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Letrozole Carbidopa Tolvaptan Febuxostat Hemihydrate Indometacin Ph. Eur. Eo2318 Quercus Ilex Allergen Extract Resiquimod Sulfate Vib1116 Mr0005 Ubamatamab Phenylalanine Octreotide Hydrochloride Dobutamine Narsoplimab Clarithromycin FLUORIDE Pemafibrate GSKVX000000070250 SOFOSBUVIR More therapies…

    Learn about Your Condition

    Penile squamous cell carcinoma Osteochondrodysplasia Autoimmune disorder Foetal growth restriction Systemic scleroderma Macular telangiectasia Pterygium Respiratory failure Narcolepsy EGFR gene mutation Decreased appetite Langerhans cell sarcoma Viral infection Follicular lymphoma Cataract More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Fulvestrant
    France

  • Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    • Lutetium (177Lu) Edotreotide
    Austria Belgium Czechia France Germany Italy +3

  • Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Ipilimumab
    • Binimetinib
    • Encorafenib
    France Germany Italy The Netherlands Poland Spain

  • Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Inavolisib
    • Fulvestrant
    • Palbociclib
    Belgium France Germany Greece Hungary Italy +3

  • Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Alpelisib
    • Fulvestrant
    Belgium Bulgaria Czechia Denmark Finland France +10

  • Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Enfortumab Vedotin
    • Durvalumab
    • Infliximab
    Austria France Germany Greece Italy The Netherlands +3

  • Study of Pembrolizumab and Chemotherapy for Patients with HR+/HER2- Advanced Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Doxorubicin Hydrochloride, Liposomal
    • Capecitabine
    • Doxorubicin
    Austria France Germany Greece Hungary Ireland +7

  • Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Doxorubicin
    • Paclitaxel
    • Pembrolizumab
    Belgium France Germany Hungary Ireland Poland +2

  • Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Bladder cancer stage II
    • Bladder cancer stage III
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Pembrolizumab
    Belgium Denmark France Germany Hungary Ireland +4

  • Study of [225Ac]Ac-PSMA-R2 for Men with Advanced Prostate Cancer Previously Treated or Not with 177Lu-PSMA Therapy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Aaa802
    • Degarelix Acetate
    • Gallium (68Ga) Psma-R2
    France
Previous Page
1 … 15 16 17 18 19 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!